Many nanomaterial platforms are now available thanks to the great work funded during the last 10-20 years. As others have stated, improved targeted delivery to tissues/cells of interest is needed. Specifically, intracellular delivery of drugs such as siRNA that cannot withstand naked transport. Tighter integration of bionanomaterials such as engineered viruses and exosomes with other nano platforms could improve delivery of therapeutic and diagnositic payloads only into target cells. This would result in achieving the desired effects despite broad distribution of the nanoparticles while minimizing off-target and adverse effects.